

UWL REPOSITORY
repository.uwl.ac.uk

Direct assessment of metabolite utilization by *Pseudomonas aeruginosa* during growth on artificial sputum medium

Behrends, Volker, Geier, Benedikt, Williams, Huw D and Bundy, Jacob G (2013) Direct assessment of metabolite utilization by *Pseudomonas aeruginosa* during growth on artificial sputum medium. *Applied and environmental microbiology*, 79 (7). pp. 2467-2470. ISSN 0099-2240

<http://dx.doi.org/10.1128/aem.03609-12>

This is the Accepted Version of the final output.

UWL repository link: <https://repository.uwl.ac.uk/id/eprint/11458/>

Alternative formats: If you require this document in an alternative format, please contact: open.research@uwl.ac.uk

Copyright: Creative Commons: Attribution 4.0

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy: If you believe that this document breaches copyright, please contact us at open.research@uwl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 **Direct assessment of metabolite utilization by *Pseudomonas aeruginosa* from artificial**
2 **sputum medium**

3

4 Volker Behrends¹, Benedikt Geier², Huw D. Williams², Jacob G. Bundy^{1*}

5

6 1 – Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK

7 2 – Department of Life Sciences, Imperial College London, London SW7 2AZ, UK

8

9 running title: Metabolite utilization by *Pseudomonas aeruginosa*

10

11 *Author for correspondence: j.bundy@imperial.ac.uk

12

13

14 **ABSTRACT**

15 We grew *Pseudomonas aeruginosa* in LB and artificial sputum medium (filtered and unfiltered),
16 and quantified metabolite utilization and excretion by NMR spectroscopy (metabolic footprinting,
17 or extracellular metabolomics). Utilization was similar between media, but there were differences
18 in excretion – e.g. acetate was produced only in unfiltered ASM.

19

20 **MAIN TEXT**

21 The opportunistic pathogen *Pseudomonas aeruginosa* is the major cause of morbidity and
22 mortality for cystic fibrosis (CF) patients (6). In order to better understand *P. aeruginosa* infection
23 it is important to create model conditions that aim to mimic those in the CF lung, such as media
24 designed to mimic the nutritional environment of sputum from CF patients. These include
25 artificial sputum medium (ASM)(11), a complex medium made up using porcine mucin, DNA and
26 amino acids, and synthetic cystic fibrosis medium (SCFM)(9), a defined medium containing
27 mainly amino acids and lactate. In addition, many studies use more conventional rich media like
28 Lysogeny Broth (LB)(4), which is based on tryptone and yeast extract. All of these media support
29 growth of *P. aeruginosa* to high cell numbers, but the question remains how the differences in
30 composition alter the physiology and metabolism of the inoculated bacteria, and hence the
31 relevance to CF infections. Generally, approaches to validating this have depended on indirect
32 means to assess metabolism – for instance, profiling gene transcription (9). However,
33 transcriptional data are often insufficient to capture the actual metabolic changes that occur as a
34 result of perturbing a bacterial cell. Because of this, we wanted to examine the actual changes in
35 metabolite utilization by *P. aeruginosa*, in a comparison of three different complex media: LB,
36 ASM (oASM, prepared according to its original recipe (11)) and a filtered version of ASM (fASM,

37 prepared according to Kirchner *et al.* (2012) (7)). (We have previously investigated metabolite
38 utilization in SCFM in depth (2), so did not include this medium again here.)

39 We grew *P. aeruginosa* wild-type PA14 in aerobic conditions in batch culture for 24h (growth
40 conditions described in detail in (2)) and sampled 0.6 ml of culture at nine time points (before
41 inoculation; hourly from two to eight hours; and then at 24h). Of these samples, 0.1 ml was used
42 for measuring optical density for LB and fASM samples (oASM is turbid and OD cannot be used
43 to monitor cell growth). The supernatants were then analysed by NMR spectroscopy as detailed
44 in Behrends *et al.* (2012) (3). The resulting spectra were assigned and integrated for each
45 medium. In total, we were able to assign 19 compounds detectable across all media, of which 18
46 could be quantified (Table 1; histidine was detected but not integrated here because of pH-
47 induced resonance frequency shifts between spectra) and normalized to compound levels in the
48 uninoculated media. Four further metabolites could be identified in at least two media. Finally,
49 the metabolite concentrations were fitted using non-linear (sigmoid) models, which allows
50 between-media comparisons of uptake and excretion time for individual compounds (2).

51 **Metabolite uptake is tightly controlled and broadly comparable in rich media** – There are
52 several possible ways in which media composition could alter bacterial physiology and therefore
53 the bacterial interaction with media. Changes can be qualitative, i.e. the same strain
54 utilizes/excretes a given compound from/into one medium, but not another; or quantitative, i.e.
55 the media composition affects the dynamics of utilization/excretion. By non-linear fitting, the time
56 dimension of a data set is compressed to produce biologically meaningful sigmoid parameters
57 that can detect both qualitative and quantitative changes – e.g. the t_{50} value corresponds to the
58 time at which half of the compound has been taken up (a compound's half-life). Some
59 metabolites, though, had complex utilization profiles, and so standard sigmoid models could not
60 be fitted; e.g. S-oxo-methionine (Figure 1). In total, 14 metabolites were successfully fitted
61 (Table 1). For these compounds, there were no differences between the media after 24h of

62 growth, as all detectable amino acids (with the exception of methionine, which was not taken up
63 from any medium) were completely depleted after 24h. In addition, the dynamics of uptake were
64 similar across all media at first glance, as the order in which metabolites were taken up was
65 broadly comparable; the most 'outlying' medium, unsurprisingly, was LB: both of the ASM media
66 were more similar to each other than to LB (Figure 2). The two ASM media had essentially
67 identical order of metabolite uptake, but metabolites were taken up slightly more quickly from
68 fASM than from oASM, possibly because oASM also contains alternative carbon sources
69 (macromolecules, lipid droplets). In addition, we also profiled *P. aeruginosa* PAO1 growth on
70 oASM, in order to permit comparison with earlier studies. While there certainly were some
71 differences from PA14, e.g. valine was used earlier by PAO1, the overall pattern of metabolite
72 usage was similar between the two backgrounds (Figure 2).

73 In agreement with previous studies (2, 8) there was a set of compounds – asparagine,
74 aspartate, alanine, glutamate (and in the case of oASM and fASM also glutamine) – that were
75 taken up early on in growth (Table 1). For these 'early-uptake' compounds, the t_{50} values
76 increased in the order LB to fASM to oASM, i.e. quickest uptake from LB and slowest from
77 oASM. Surprisingly, this order of uptake was reversed for the late-uptake metabolites.
78 Threonine, phenylalanine and tryptophan had t_{50} values of less than 12h for all media . In
79 contrast, glycine, lysine, isoleucine and valine were only taken up after 12h from LB, but
80 between 7 to 11h from the ASM media (Table 1; Figure 2). Compound uptake in *Pseudomonas*
81 is tightly controlled by catabolite repression, which affects amino acids and other organic acids
82 as well as carbohydrates (5, 8, 10). The most likely explanation for the surprising delay in the
83 utilization of late-uptake metabolites from LB is catabolite repression by a metabolite found in LB
84 but not in the two ASM media. Trehalose is a good candidate for this metabolite: it is present in
85 LB but not ASM, and was taken up after the early-uptake but before the late-uptake metabolites
86 (Figure 2). There is little information on catabolite repression by trehalose for *Pseudomonas*

87 species (10). In order to test this, we repeated the experiment, but with trehalose spiked into
88 oASM at 2 mM concentration. This demonstrated that trehalose is not, in fact, causing the
89 catabolite repression: the order of metabolite uptake was essentially identical for the two ASM
90 media, regardless of the presence of trehalose (data not shown). The putative repressing
91 compound in LB remains to be elucidated.

92 **Metabolite excretion differs between media**

93 In contrast to uptake, compound excretion was noticeably different between the media. The
94 biggest difference was found when comparing oASM and fASM: acetate was only found in
95 significant amounts in the oASM samples (Figure 1). As the media only differ in a final filtration
96 step, the filtration must remove one or several acetogenic substrates. The turbidity of oASM
97 medium is (at least partly) because of suspended lipid droplets. The lipid fatty acids are
98 metabolized via acetyl-CoA, and so the acetate seen in oASM is potentially the product of
99 overflow metabolism to protect the CoA pool of the cell (12). To test this, we repeated the
100 experiment with oASM, but omitted the egg yolk (a major source of lipids). In non egg-yolk
101 containing ASM, the acetate production was significantly reduced compared to standard oASM
102 (at maximum after 8h, levels were at 40 % of levels in oASM, $p < 0.02$, T-Test), but was still
103 significantly higher than in fASM (after 8h, levels were 15x higher, $p < 0.01$, T-Test). Therefore,
104 we conclude that the egg yolk is an acetogenic substrate in oASM, but is not the only one.
105 These are potentially important differences between the two versions of ASM, given that acetate
106 excretion by *P. aeruginosa* CF clinical isolates has been linked to the length of infection (and
107 hence metabolic adaptation to lung conditions)(1). Formate excretion also differed between the
108 media, with levels in fASM and LB higher than in oASM (Figure 1).

109 In addition to fermentation products, several low concentration metabolites were detectable
110 above baseline after 24 h incubation, and some of these were clearly different between fASM
111 and oASM (data not shown). In-depth characterization of these compounds is beyond the scope

112 of our current study, but indicates that there could be other specific medium-dependent
113 metabolic differences – which could well be related to cellular signalling, for instance. In
114 summary, direct analysis of changing exometabolomic profiles can highlight bacterial responses
115 to different media; *Pseudomonas aeruginosa* metabolite uptake is broadly comparable across
116 different rich media (and very similar between the filtered and unfiltered versions of ASM), but
117 changes in metabolite excretion indicate that there are also differences in cellular metabolism
118 between media.

119 **Acknowledgements.**

120 We thank the anonymous reviewers of our manuscript, who made helpful suggestions for
121 improving the paper.

122

- 123 1. **Behrends V, Ryall B, Zlosnik JEA, Speert DP, Bundy JG, Williams HD.** 2012.
124 Metabolic adaptations of *Pseudomonas aeruginosa* during cystic fibrosis chronic lung
125 infections. *Environ Microbiol*, doi: 10.1111/j.1462-2920.2012.02840.x.
- 126 2. **Behrends V, Ebbels TMD, Williams HD, Bundy JG.** 2009. Time-resolved metabolic
127 footprinting for nonlinear modeling of bacterial substrate utilization. *Appl Environ Microbiol*
128 **75**:2453–2463.
- 129 3. **Behrends V, Williams KJ, Jenkins VA, Robertson BD, Bundy JG.** 2012. Free
130 Glucosylglycerate Is a Novel Marker of Nitrogen Stress in *Mycobacterium smegmatis*. *J*
131 *Proteome Res* **11**:3888–3896.
- 132 4. **Bertani G.** 1951. Studies on lysogenesis. I. The mode of phage liberation by lysogenic
133 *Escherichia coli*. *J Bacteriol* **62**:293–300.
- 134 5. **Browne P, Barret M, O’Gara F, Morrissey JP.** 2010. Computational prediction of the Crc
135 regulon identifies genus-wide and species-specific targets of catabolite repression control

136 in *Pseudomonas* bacteria. *BMC Microbiol* **10**:300.

137 6. **Davies JC, Alton EFW, Bush A.** 2007. Cystic fibrosis. *BMJ* **335**:1255–1259.

138 7. **Kirchner S, Fothergill JL, Wright EA, James CE, Mowat E, Winstanley C.** 2012. Use
139 of artificial sputum medium to test antibiotic efficacy against *Pseudomonas aeruginosa* in
140 conditions more relevant to the cystic fibrosis lung. *J Vis Exp* e3857.

141 8. **Moreno R, Martínez-Gomariz M, Yuste L, Gil C, Rojo F.** 2009. The *Pseudomonas*
142 *putida* Crc global regulator controls the hierarchical assimilation of amino acids in a
143 complete medium: Evidence from proteomic and genomic analyses. *Proteomics* **9**:2910–
144 2928.

145 9. **Palmer KL, Aye LM, Whiteley M.** 2007. Nutritional cues control *Pseudomonas*
146 *aeruginosa* multicellular behavior in cystic fibrosis sputum. *J Bacteriol* **189**:8079–8087.

147 10. **Rojo F.** 2010. Carbon catabolite repression in *Pseudomonas* : optimizing metabolic
148 versatility and interactions with the environment. *FEMS Microbiol Rev* **34**:658–684.

149 11. **Sriramulu DD, Lünsdorf H, Lam JS, Römling U.** 2005. Microcolony formation: a novel
150 biofilm model of *Pseudomonas aeruginosa* for the cystic fibrosis lung. *J Med Microbiol*
151 **54**:667–676.

152 12. **Wolfe AJ.** 2005. The acetate switch. *Microbiol Mol Biol Rev* **69**:12–50.


153

154

155 Table 1. Fitted compound half-life (t_{50}) values derived from sigmoid fits of concentration data for
 156 metabolites found in all three growth media.

t_{50}	oASM		fASM		LB		oASM (PA)
	mean	S.D.	mean	S.D.	mean	S.D.	mean
Asparagine	3.55	0.28	1.98	0.19	1.03	0.03	2.91
Aspartate	4.15	0.20	4.17	0.07	3.02	0.16	4.19
Alanine	4.96	0.56	3.41	0.06	2.74	0.05	4.24
Glutamate	5.11	0.33	4.24	0.03	3.03	0.10	4.42
Isoleucine	8.56	0.18	8.62	0.75	> 12	nd	5.99
Leucine	9.39	0.78	7.25	0.06	> 12	nd	5.99
Lysine	10.12	1.85	8.12	0.54	> 12	nd	7.36
Glycine	10.16	0.73	8.99	0.57	> 12	nd	8.90
Threonine	10.48	0.71	8.13	0.12	9.07	0.28	8.34
Phenylalanine	10.66	0.20	7.91	0.05	11.14	0.00	8.23
Tryptophan	11.55	1.65	8.09	0.12	9.19	0.27	> 12
Tyrosine	> 12	nd	10.92	1.52	> 12	nd	11.83
Methionine	> 12	nd	> 12	nd	> 12	nd	> 12
Valine	> 12	nd	> 12	nd	> 12	nd	9.51

157



158

159

